[{"Assets_0_Q2_USD":344786000.0,"CommonStockSharesOutstanding_0_Q2_shares":141908000.0,"EarningsPerShareBasic_1_Q2_USD":-0.23,"EarningsPerShareBasic_2_Q2_USD":-0.48,"NetIncomeLoss_1_Q2_USD":-30763000.0,"NetIncomeLoss_2_Q2_USD":-63660000.0,"StockholdersEquity_0_Q2_USD":58165000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":134013000.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":131300000.0,"Ticker":"HALO","CIK":"1159036","name":"HALOZYME THERAPEUTICS INC","OfficialName":"Halozyme Therapeutics Inc. Common Stock","form":"10-Q","period":"20170630","fy":"2017.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"5856719603.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Biological Products (No Diagnostic Substances)","Market":"NASDAQ","SP500":"nan","filed":"20170808"}]